Maximizing Weight Loss After Roux-en-Y Gastric Bypass May Decrease Risk of Incident Organ Cancer.

Area of Science:

• Bariatric surgery
• Oncology
• Metabolic health

Background:

• Emerging evidence suggests metabolic surgery can lower cancer incidence.
• Roux-en-Y gastric bypass (RYGB) is a common bariatric procedure.
• The relationship between weight loss extent and cancer risk post-RYGB requires further investigation.

Purpose of the Study:

• To investigate the association between the degree of weight loss achieved after RYGB and the subsequent risk of developing incident organ cancer.
• To quantify the impact of % total body weight loss (%TWL) on cancer development in patients undergoing RYGB.

Main Methods:

• Retrospective review of 2943 patients who underwent RYGB without a prior cancer history.
• Incident organ cancer was identified through electronic health records, a tumor registry, and chart review.
• Kaplan-Meier analysis estimated cancer incidence, while repeated measures linear regression compared %TWL between cancer and non-cancer groups, adjusting for covariates.

Main Results:

• 1.8% of patients (54 out of 2943) developed incident organ cancer within a median follow-up of 3.8 years.
• Kaplan-Meier estimates showed cancer incidence at 3, 5, and 10 years post-surgery as 1.3%, 2.5%, and 4.2%, respectively.
• Patients who developed cancer had significantly less weight loss (-1.5% TWL) compared to those who did not, after adjusting for key demographic and clinical factors (p=0.034).

Conclusions:

• Increased weight loss following RYGB is associated with a reduced risk of developing organ cancer.
• The extent of weight reduction may play a crucial role in the cancer-protective effects observed after metabolic surgery.
• These findings underscore the importance of maximizing weight loss in bariatric surgery for potential long-term oncological benefits.